某三甲医院对重点监控药品实施药事管理措施的效果

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (939 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effects of pharmaceutical administration measures on key monitored drugs in a grade Ⅲ hospital so as to provide reference for promoting rational clinical drug use. Methods From 2020, a hospital implemented pharmaceutical administration of key monitored drugs by establishing a list of key monitored drugs, setting up monitoring indicators, carrying out special comments, including performance assessment, etc. Data indicators such as the number of key monitored drugs, purchase amount, ratio of drug consumption to total drug consumption, utilization rate of inpatients and average drug consumption were compared and analyzed from 2019 to 2022. Results The number of key monitored drugs decreased from 40 in 2019 to 26 in 2022, and the purchase amount decreased by 66.42%. The proportion of drug consumption decreased from 10.59% to 6.46% with the application rate in inpatients decreasing from 70.51% to 44.59%. The average drug consumption of inpatients decreased from 2104.65 yuan to 1515.08 yuan, a decrease of 28.01%. Conclusions Through a series of pharmaceutical administration measures,the drug indexes of key monitored drugs in the hospital have decr eased significantly, and the effects of promoting clinical rational drug use is more obvious.

Key words： key monitored drug pharmaceutical administration clinical application rational drug use

Received: 19 May 2023

ZTFLH:

R95

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Yushu
	SHANG Xiaolin
	ZHAO Chuan
	andZHANG Wei

Cite this article:

GUO Yushu,SHANG Xiaolin,ZHAO Chuan等. Effects of pharmaceutical administration measures on key monitored drugs in a grade Ⅲ hospital[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(10): 857-860.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2023/V34/I10/857

[1]	国家卫生健康委办公厅.关于做好辅助用药临床应用管理有关工作的通知[S].国卫办医函
	[2018]1112 号 2018-12-12.
[2]	国家卫生健康委办公厅, 国家中医药局办公室.关于印发第一批国家重点监控合理用药药品目录(化药及生物制品)的通知[S].国卫办医函
	[2019]558号2019-06-11.
[3]	梁广楷, 扶宇, 李俊蕾, 等. 重点监控药品政策对样本地区辅助用药使用的影响研究[J]. 中国药学杂志, 2018, 53(18):1614-1618.
[4]	陈冰清, 王欣怡,叶桦. 我国各省建立重点药品监控制度的比较[J]. 中国药事, 2018, 32(10): 1314-1321.
[5]	鞠晓宇, 程杰, 关胜江, 等. 量化评分体系在辅助用药动态监控中的应用[J]. 中国药物评价, 2020, 37(2): 144-147.
[6]	王笛, 王相峰, 毛丽超, 等. 我国医疗机构重点监控药品监测平台合理应用管理指标的探讨[J].中国药房, 2021, 32(8):911-914.
[7]	沈云珠, 张吟, 施晓宁, 等.多种管控和干预手段促进辅助药品的合理使用[J]. 中国药事, 2020, 34(6): 707-713.
[8]	刘慧, 战寒秋. 重点监控药品的管理模式探索[J]. 临床药物治疗杂志, 2020, 18(11):86-89.
[9]	刘相端, 司倩, 方圆, 等.我院重点监控药品监管前后合理用药指标变化[J]. 药物流行病学杂志, 2019, 28(5):337-341.
[10]	杨静, 郑磊, 陈莉, 等. 我院辅助治疗药物临床使用管理模式的建立[J]. 中国药房, 2017, 28(25):3545-3548.
[11]	陈凯骏. 医保控费形势下重点监控药品管控模式的构建[J]. 中医药管理杂志, 2021, 29(19):123-124.
[12]	黄辉, 单海华, 连一新, 等. 医药价格改革背景下医院药品管控的实践与探索[J]. 中国医院管理, 2019, 39(5):73-74.
[13]	杨香瑜, 陈辰, 胡松, 等. 基于疾病诊断相关分组实施重点监控药品精细化管理的实践[J]. 中国医院用药评价与分析, 2021, 21(5): 612-615.
[14]	贾立华, 赵振满, 贾娜娜, 等. 临床药师参与抗肿瘤辅助用药医嘱审核及干预效果分析[J]. 中国药房, 2013, 24(39): 3739-3742.
[15]	蒋林, 袁珺, 肖腊梅, 等. 临床药师参与重点监控药品医嘱点评及干预效果[J]. 临床合理用药, 2020, 13(8):7-12.